Synlogic to discontinue Synpheny-3 study, evaluate strategic options

Synlogic announced the decision to discontinue Synpheny-3, its ongoing pivotal study of labafenogene marselecobac SYNB1934 as a potential treatment for phenylketonuria PKU . As a result, Synlogic’s management and its Board of Directors have made the decision to evaluate strategic options for the Company. The decision to end Synpheny-3 is based on results of an internal review in advance of an upcoming independent Data Monitoring Committee DMC assessment, which indicated the trial was unlikely to meet its primary endpoint. The decision was not based on concerns regarding safety or tolerability. Synlogic will now work with the Synpheny-3 clinical trial sites involved to implement the discontinuation. “It is with a heavy heart that we share this news, and our resulting decision to end Synpheny-3. Based on the program’s progress and data to date, we had expected the study to demonstrate the potential for SYNB1934 to provide an important new treatment option for those affected by PKU,” said Aoife Brennan, M.B. Ch.B., Synlogic President and Chief Executive Officer. “We express our deep gratitude for the support and partnership we have received from the PKU community, including the clinical trial site investigators and staff.” Synlogic’s Board of Directors plans to conduct an assessment of strategic options to enhance shareholder value, which will include, but are not limited to, an acquisition, merger, reverse merger, other business combination, sales of assets, dissolution or other strategic transactions. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements will be reached, or transactions will be successfully consummated or on attractive terms. As a result of this process, Synlogic will cease operations, and reduce its workforce by more than 90%, retaining only certain employees to assist in the strategic review and assist in the discontinuation of the study. The majority of impacted roles will end in February 2024. Our cash, cash equivalents and short-term investments balance at December 31, 2023 was $47.7M… Dr. Brennan is also departing as President and Chief Executive Officer as part of the reduction, and stepping down from the Board of Directors. .